High dose of ascorbic acid induces cell death in mesothelioma cells

Biochemical and Biophysical Research Communications

Volumn 394, Issue 2, 2010, Pages 249-253

  Takemura, Yukitoshi ^a   Satoh, Motohiko ^a   Satoh, Kiyotoshi ^a   Hamada, Hironobu ^b   Sekido, Yoshitaka ^c,d   Kubota, Shunichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Ascorbic acid; Cell death; Mesothelioma; Reactive oxygen species

Indexed keywords

ASCORBIC ACID; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; ASCORBIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MESOTHELIOMA; MICE; MICE, SCID; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77950296126     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.012     Document Type: Article

References (34)

1. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 353 (2005) 1591-1603
2. Peto J., Decarli A., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br. J. Cancer 79 (1999) 666-672
3. Stahel R.A., and Weder W. Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?. Curr. Opin. Oncol. 21 (2009) 124-130
4. Levine M., Espey M.G., and Chen Q. Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Radic. Biol. Med. 47 (2009) 27-29
5. Cameron E., Campbell A., and Jack T. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem. Biol. Interact. 11 (1975) 387-393
6. Cameron E., and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA 73 (1976) 3685-3689
7. Cameron E., and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA 75 (1978) 4538-4542
8. Creagan E.T., Moertel C.G., O'Fallon J.R., Schutt A.J., O'Connell M.J., Rubin J., and Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N. Engl. J. Med. 301 (1979) 687-690
9. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., and Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N. Engl. J. Med. 312 (1985) 137-141
10. Chen Q., Espey M.G., Krishna M.C., Mitchell J.B., Corpe C.P., Buettner G.R., Shacter E., and Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. USA 102 (2005) 13604-13609
11. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., Wesley R.A., and Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med. 140 (2004) 533-537
12. Chen Q., Espey M.G., Sun A.Y., Pooput C., Kirk K.L., Krishna M.C., Khosh D.B., Drisko J., and Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. USA 105 (2008) 11105-11109
13. Riordan N.H., Riordan H.D., and Casciari J.P. Clinical and experimental experiences with intravenous vitamin C. J. Orthomol. Med. 15 (2000) 201-213
14. Riordan H.D., Riordan N.H., Casciari J.J., Hunninghake R., González M.J., Mora E.M., Miranda-Massari J.R., Rosario N., and Rivera A. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P. R. Health Sci. J. 23 (2004) 115-118
15. Padayatty S.J., Riordan H.D., Hewitt S.M., Katz A., Hoffer L.J., and Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (2006) 937-942
16. Yeom C.H., Jung G.C., and Song K.J. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J. Korean Med. Sci. 22 (2007) 7-11
17. Arakawa N., Nemoto S., Suzuki E., and Otsuka M. Role of hydrogen peroxide in the inhibitory effect of ascorbate on cell growth. J. Nutr. Sci. Vitaminol. (Tokyo) 40 (1994) 219-227
18. Clement M.V., Ramalingam J., Long L.H., and Halliwell B. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid. Redox Signal. 3 (2001) 157-163
19. Chen Q., Espey M.G., Sun A.Y., Lee J.H., Krishna M.C., Shacter E., Choyke P.L., Pooput C., Kirk K.L., Buettner G.R., and Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. USA 104 (2007) 8749-8754
20. 2 induce apoptosis through Fenton chemistry independent of the cellular thiol state. Free Radic. Biol. Med. 30 (2001) 1008-1018
21. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc. Res. 68 (2005) 26-36
22. Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., and Hida T. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 97 (2006) 387-394
23. Yokoyama A., Kohno N., Fujino S., Hamada H., Inoue Y., Fujioka S., and Hiwada K. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol. Rep. 1 (1994) 507-511
24. Nakataki E., Yano S., Matsumori Y., Goto H., Kakiuchi S., Muguruma H., Bando Y., Uehara H., Hamada H., Kito K., Yokoyama A., and Sone S. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 97 (2006) 183-191
25. Mitchell J.B., Samuni A., Krishna M.C., DeGraff W.G., Ahn M.S., Samuni U., and Russo A. Biologically active metal-independent superoxide dismutase mimics. Biochemistry 29 (1990) 2802-2807
26. - {radical dot} or as SOD mimics?. J. Biol. Chem. 271 (1996) 26026-26031
27. Chatterjee P.K., Cuzzocrea S., Brown P.A., Zacharowski K., Stewart K.N., Mota-Filipe H., and Thiemermann C. Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int. 58 (2000) 658-673
28. Sasaki H., Lin L.R., Yokoyama T., Sevilla M.D., Reddy V.N., and Giblin F.J. TEMPOL protects against lens DNA strand breaks and cataract in the X-rayed rabbit. Invest. Ophthalmol. Vis. Sci. 39 (1998) 544-552
29. Murrell G.A., Francis M.J., and Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J. 265 (1990) 659-665
30. Ohguro N., Fukuda M., Sasabe T., and Tano Y. Concentration dependent effects of hydrogen peroxide on lens epithelial cells. Br. J. Ophthalmol. 83 (1999) 1064-1068
31. Liu S.L., Lin X., Shi D.Y., Cheng J., Wu C.Q., and Zhang Y.D. Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways. Arch. Biochem. Biophys. 406 (2002) 173-182
32. Galaris D., Skiada V., and Barbouti A. Redox signaling and cancer: the role of "labile" iron. Cancer Lett. 266 (2008) 21-29
33. López-Lázaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 252 (2007) 1-8
34. Planting A.S., Schellens J.H., Goey S.H., van der Burg M.E., de Boer-Dennert M., Stoter G., and Verweij J. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann. Oncol. 5 (1994) 373-374